AAAAAA

   
Results: 1-3 |
Results: 3
Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy
Authors: Khan, OA Zvartau-Hind, M Caon, C Din, MU Cochran, M Lisak, D Tselis, AC Kamholz, JA Garbern, JY Lisak, RP
Citation: Oa. Khan et al., Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy, MULT SCLER, 7(3), 2001, pp. 185-188
Appropriate design and outcome measures in multiple sclerosis clinical trials - Response
Authors: Khan, OA Tselis, AC Kamholz, JA Garbern, JY Lewis, RA Lisak, RP
Citation: Oa. Khan et al., Appropriate design and outcome measures in multiple sclerosis clinical trials - Response, EUR J NEUR, 8(5), 2001, pp. 505-506
A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFN beta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis
Authors: Khan, OA Tselis, AC Kamholz, JA Garbern, JY Lewis, RA Lisak, RP
Citation: Oa. Khan et al., A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFN beta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis, EUR J NEUR, 8(2), 2001, pp. 141-148
Risultati: 1-3 |